AOD9604

AOD9604 (Anti-Obesity Drug 9604) is a modified fragment of the C-terminus of human growth hormone, specifically the 177–191 sequence with an added tyrosine residue for stability. It was originally developed in Australia as a candidate obesity therapeutic.

AOD9604 is the piece of growth hormone that researchers isolated specifically for its fat-burning signal — without the muscle-growth or blood-sugar effects of full HGH. Think of it as the 'fat-only' fragment.

Mimics the lipolytic (fat-releasing) action of native hGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing lipolysis and inhibiting lipogenesis. Unlike full HGH it does not bind the GH receptor and does not raise IGF-1 or affect glucose tolerance in research models.

• •Adipocyte lipolysis studies
• •Obesity and body-composition research
• •Cartilage repair models
• •Comparison with HGH Fragment 176-191
• •Metabolic syndrome research

Frequently discussed in fat-loss and recomposition forums as a 'gentle' alternative to HGH-Frag 176-191. People debate whether the added tyrosine meaningfully changes outcomes versus the unmodified fragment. Often listed in cosmetic-injection conversations for localized fat research.

“The fat-burning piece of growth hormone, minus the side effects.”

Commonly paired with CJC-1295/Ipamorelin in body-composition stacks and compared head-to-head with HGH Fragment 176-191 and Tesamorelin.

AOD9604 is a modified hGH 176-191 fragment studied for selective lipolysis without the IGF-1 or glycemic effects of full growth hormone.